{"transactions":[{"id":1066692,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-08-14T16:18:12.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078637","document":"tm2523440-3_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925078637/tm2523440-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066691,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-08-14T16:18:12.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078637","document":"tm2523440-3_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925078637/tm2523440-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066690,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-08-14T16:18:12.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078637","document":"tm2523440-3_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925078637/tm2523440-3_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1079876,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Shares","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-29","kind":"purchase","planned":false,"acquired":true,"shares":539100,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."}],"balance_after":539100,"derivative":{"underlying":"Common Shares","underlying_shares":539100},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079875,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079874,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079873,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079872,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."}],"balance_after":2435029,"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079871,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":2315229,"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1079870,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-29T20:18:49.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":2195429,"source":{"system":"sec-edgar","filing":"0001104659-25-071857","document":"tm2521929-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465925071857/tm2521929-1_4seq1.xml","form_type":"4"}},{"id":1443144,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 2 Preferred Shares, no par value","published_at":"2024-08-02T16:15:50.000Z","date":"2024-07-31","kind":"exercise","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-24-085375","document":"tm2420441-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465924085375/tm2420441-2_4seq1.xml","form_type":"4"}},{"id":1443143,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2024-08-02T16:15:50.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."}],"balance_after":465116,"derivative":{"underlying":"Common Shares","underlying_shares":465116},"source":{"system":"sec-edgar","filing":"0001104659-24-085375","document":"tm2420441-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465924085375/tm2420441-2_4seq1.xml","form_type":"4"}},{"id":1443142,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2024-08-02T16:15:50.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":465116,"derivative":{"underlying":"Common Shares","underlying_shares":465116},"source":{"system":"sec-edgar","filing":"0001104659-24-085375","document":"tm2420441-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465924085375/tm2420441-2_4seq1.xml","form_type":"4"}},{"id":1443141,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2024-08-02T16:15:50.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."}],"balance_after":465116,"derivative":{"underlying":"Common Shares","underlying_shares":465116},"source":{"system":"sec-edgar","filing":"0001104659-24-085375","document":"tm2420441-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465924085375/tm2420441-2_4seq1.xml","form_type":"4"}},{"id":1443140,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-08-02T16:15:50.000Z","date":"2024-07-31","kind":"exercise","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."}],"balance_after":2075629,"source":{"system":"sec-edgar","filing":"0001104659-24-085375","document":"tm2420441-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465924085375/tm2420441-2_4seq1.xml","form_type":"4"}},{"id":1443139,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76524,"kind":"person","name":"Title 19 Promis","position":1,"cik":"0002005531","reported_name":"Title 19 Promis","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-08-02T16:15:50.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."}],"balance_after":1575629,"source":{"system":"sec-edgar","filing":"0001104659-24-085375","document":"tm2420441-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005531/000110465924085375/tm2420441-2_4seq1.xml","form_type":"4"}}]}